
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is projected to experience significant revenue growth, with an estimated increase in international revenue from approximately $50 million in FY25 to nearly $1 billion by FY30, reflecting a tenfold enhancement driven by the expansion of treatment options and international market entry. Additionally, core U.S. revenue is forecasted to grow at an annual rate of about 21%, primarily fueled by a rise in subscriber numbers and enhancements to revenue per subscriber through personalization and new treatment offerings. The growing trend towards private healthcare, particularly in markets such as the UK, further supports the positive outlook, as evidenced by a notable increase in private insurance adoption in recent years.
Bears say
Hims & Hers Health has experienced a significant decline in stock value, dropping over 20% since late July despite an initial doubling of shares year-to-date, indicating growing concerns regarding slowing core growth. Key risks include the potential for slower adoption of personalized treatments, regulatory challenges that could affect the business model, difficulties in maintaining revenue growth while achieving operating leverage, and increasing competition in the digital health sector. These factors contribute to a negative outlook for the company's financial performance moving forward.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares